Key Factors in Determining the Treatment of Acute Lymphoblastic Leukemia
This information was originally presented at the NCCN 2017 Nursing Forum: Oncology Nursing in Hematologic Malignancies held in San Francisco, California, on October 6, 2017.
This educational program is designed to meet the educational needs of oncology nurses who manage patients with hematologic malignancies.
Following this activity, participants should be able to:
- Outline key factors that determine treatment of acute lymphoblastic leukemia
- Summarize treatment strategies in the management of relapsed or refractory acute lymphoblastic leukemia and associated adverse events
Stephany L. Rodriguez, RN, MS, ANP
UCSF Helen Diller Family Comprehensive Cancer Center
Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.
The faculty listed below discloses the following relevant financial relationships:
Stephany L. Rodriguez, RN, MS, ANP
*Orchard Therapeutics, Ltd.: Salary
Seattle Genetics: Product/Speakers Bureau
* signifies the relationship relates to the individual's spouse/partner
The NCCN Activity Planning staff listed below discloses no relevant financial relationships:
Kimberly Bayer; Robert W. Carlson, MD; Melissa Esplen; Mark Geisler; Kristina M. Gregory, RN, MSN, OCN; Donald Harting, MA, ELS, CHCP; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Lisa Kimbro, MBA, CPA; Joan S. McClure, MS; Diane McPherson; Melanie Moletzsky; Lisa Perfidio; Liz Rieder; Shannon K. Ryan; Kathy Smith; Melinda Somasekhar, PhD (employed by NCCN until 10/30/17); Gary J. Weyhmuller, MBA, SPHR
The NCCN Clinical Information staff listed below, who has reviewed content, discloses no relevant financial relationships:
Ndiya Ogba, PhD
The ACCME/ANCC/ACPE defines “conflict of interest” as when an individual has an opportunity to affect CE content about products or services of a commercial interest with which he/she has a financial relationship.
ACCME, ACPE, and ANCC focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CE activity. ACCME, ACPE, and ANCC have not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME, ACPE, and ANCC defines “relevant” financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation to the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.
National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
NCCN designates this educational activity for a maximum of 0.54 contact hours.
- 0.54 ANCC contact hours
- 0.54 Participation